| Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus NCT01144338 | Completed | P3 | AstraZeneca |
| A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650 NCT01455896 | Completed | P3 | Intarcia Therapeutics |
| A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both. NCT00717457 | Completed | P3 | Hoffmann-La Roche |
| A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes NCT00960661 | Completed | P3 | AstraZeneca |
| Exenatide Versus Glimepiride in Patients With Type 2 Diabetes NCT00359762 | Completed | P3 | AstraZeneca |
| Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) NCT00676338 | Completed | P3 | AstraZeneca |
| Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus NCT00035984 | Completed | P3 | AstraZeneca |
| A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects NCT00917267 | Completed | P3 | AstraZeneca |
| GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin NCT00707031 | Completed | P3 | Sanofi |
| Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy NCT04504396 | Completed | P3 | PegBio Co., Ltd. |
| Effect of AC2993 Compared With Insulin Glargine in Patients With Type 2 Diabetes Also Using Combination Therapy With Sulfonylurea and Metformin NCT00082381 | Completed | P3 | AstraZeneca |
| A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes NCT01455870 | Completed | P3 | Intarcia Therapeutics |
| A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2) NCT00637273 | Completed | P3 | AstraZeneca |
| Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin NCT00082407 | Completed | P3 | AstraZeneca |
| Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes NCT00434954 | Completed | P3 | AstraZeneca |
| Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3) NCT00641056 | Completed | P3 | AstraZeneca |
| Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin NCT00324363 | Completed | P3 | AstraZeneca |
| A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes NCT01455857 | Completed | P3 | Intarcia Therapeutics |
| Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes NCT00111540 | Completed | P3 | AstraZeneca |
| The Effectivity and Safety Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus NCT03239119 | Unknown | P3 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
| Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus NCT00935532 | Completed | P3 | AstraZeneca |
| A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes NCT02119819 | Completed | P2 | OPKO Health, Inc. |
| Comparison of Exenatide Taken Before Lunch and Dinner With Before Breakfast and Dinner in Patients With Type 2 Diabetes NCT00359879 | Completed | P3 | AstraZeneca |
| Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea NCT00039026 | Completed | P3 | AstraZeneca |
| Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes NCT01652716 | Completed | P3 | AstraZeneca |
| Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea. NCT00313001 | Completed | P3 | Novo Nordisk A/S |
| Comparison Study of the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly Suspension to Sitagliptin and Placebo in Subjects With Type 2 Diabetes Mellitus NCT01652729 | Completed | P3 | AstraZeneca |
| Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only NCT00518115 | Completed | P2 | GlaxoSmithKline |
| Efficacy and Safety of Basal Insulin Glargine Combination With Exenatide Bid vs Aspart30 in T2DM NCT02467920 | Completed | P4 | Huazhong University of Science and Technology |
| Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide NCT00560417 | Completed | P3 | Eli Lilly and Company |
| Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With Metformin NCT00039013 | Completed | P3 | AstraZeneca |
| Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) NCT00308139 | Completed | P3 | AstraZeneca |
| An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus NCT01876849 | Completed | P3 | AstraZeneca |
| Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects NCT04504370 | Completed | P3 | PegBio Co., Ltd. |
| A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Placebo in T2DM Patients NCT06254014 | Active, not recruiting | P3 | Beijing Dongfang Biotech Co., Ltd. |
| Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus NCT00765817 | Completed | P3 | AstraZeneca |
| A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin NCT00870194 | Completed | P4 | AstraZeneca |
| A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5) NCT00877890 | Completed | P3 | AstraZeneca |
| Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin NCT03060980 | Terminated | P3 | Intarcia Therapeutics |
| Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes. NCT02288273 | Completed | P4 | AstraZeneca |
| A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients NCT00360334 | Completed | P3 | AstraZeneca |
| Safety and Efficacy of Exenatide as Monotherapy NCT00381342 | Completed | P3 | AstraZeneca |
| Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes NCT03297879 | Completed | P4 | Beijing Chao Yang Hospital |
| Extension Study for 2993-112 NCT01789957 | Completed | P3 | AstraZeneca |
| Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes NCT01003184 | Completed | P3 | AstraZeneca |
| Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes NCT02081118 | Completed | P2 | Hanmi Pharmaceutical Company Limited |
| A Study of the Effect of Glucagon-like Peptide 1(GLP-1) Receptor Agonist in Combination With Metformin Therapy on Diabetes Remission in Subjects With Newly Diagnosed Type 2 Diabetes Who Are Overweight or Obese NCT03018665 | Unknown | P4 | The First Hospital of Jilin University |
| Effect on Weight Loss of Exenatide Versus Placebo NCT00375492 | Completed | P3 | AstraZeneca |
| Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin NCT00099320 | Completed | P3 | AstraZeneca |
| Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) NCT00577824 | Completed | P3 | AstraZeneca |
| Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin NCT00603239 | Completed | P3 | AstraZeneca |
| The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients NCT01270191 | Unknown | P4 | Taipei Veterans General Hospital, Taiwan |
| Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients NCT01776788 | Completed | P4 | The First Affiliated Hospital of Xiamen University |
| Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus NCT00044694 | Completed | P2 | AstraZeneca |
| Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus NCT00943917 | Completed | P2 | Intarcia Therapeutics |
| Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination NCT00044668 | Completed | P3 | AstraZeneca |
| A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes NCT00382239 | Completed | P2 | AstraZeneca |
| Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes NCT02449603 | Completed | P4 | Xijing Hospital |
| Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes NCT02455076 | Completed | P4 | Emory University |
| Effect of Bydureon on Carotid Atherosclerosis Progression in Type 2 Diabetes Mellitus NCT02162550 | Unknown | P4 | Phoenix VA Health Care System |